Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity

Area of Science:

• Biotechnology
• Immunology
• Materials Science

Background:

• Current combination therapies for complex diseases using monoclonal antibodies (mAbs) have limitations.
• These limitations include inconvenient administration, suboptimal cooperative effects, poor pharmacokinetics, and insufficient tumor accumulation.

Purpose of the Study:

• To develop a novel multicomponent nano antibody array (PL-RB) for improved cancer treatment.
• To overcome the limitations of traditional combination antibody therapies.

Main Methods:

• Constructed a multifunctional antibody nanoarray (PL-RB) using type I/II anti-CD20 mAbs.
• The nanoarray arms distinct mAbs with cooperative effectors onto a long chain, forming a comb-like structure.
• Evaluated the pharmacokinetics, antigen targeting, and anti-lymphoma efficiency of the PL-RB.

Main Results:

• The PL-RB demonstrated improved pharmacokinetics compared to dissociative parental mAbs.
• It simultaneously targets distinct epitopes on single and neighboring antigens, inducing potent apoptosis activity.
• PL-RB evoked apoptosis, complement-dependent cytotoxicity (CDC), and antibody-dependent cellular cytotoxicity (ADCC), synergistically promoted by the enhanced permeability and retention (EPR) effect.
• Achieved high intratumor accumulation and excellent anti-lymphoma efficiency.

Conclusions:

• The multifunctional antibody nanoarray (PL-RB) offers a promising strategy for cancer therapy.
• This approach enhances therapeutic efficacy through improved pharmacokinetics, targeted antigen cross-linking, and synergistic immune responses.
• The PL-RB shows significant potential for treating lymphoma and other complex diseases.